Paul Rivard - 24 Aug 2023 Form 4 Insider Report for MyMD Pharmaceuticals, Inc. (TNFA)

Reporting relationship: Chief Legal Officer
Issuer ticker: TNFA
Reported as of: 24 Aug 2023
Net transaction value: +$166,500
SEC form: 4
Accepted by SEC: 24 Aug 2023, 17:58:33 UTC
Prior SEC filing: 18 Aug 2023
Source filing: View source filing
Reporting owner signature: /s/ Paul Rivard

Key filing fact

Paul Rivard filed Form 4 for MyMD Pharmaceuticals, Inc. (TNFA) on 24 Aug 2023.

Key facts

This page summarizes Paul Rivard's Form 4 filing for MyMD Pharmaceuticals, Inc. (TNFA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Aug 2023, 17:58.

Change

Previous filing in this sequence was filed on 18 Aug 2023.
Current net transaction value: +$166,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MYMD transaction

Common stock

Purchase

Transaction value: $166,500
Shares: +150,000
Change %: +60%
Price: $1.11
Shares after: 400,000
Date: 24 Aug 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.045 to $1.15, inclusive. The reporting person undertakes to provide to MyMD Pharmaceuticals, Inc., any security holder of MyMD Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.